ATE491723T1 - Neue verbindungen mit gemischter amylin aktivität - Google Patents
Neue verbindungen mit gemischter amylin aktivitätInfo
- Publication number
- ATE491723T1 ATE491723T1 AT99906782T AT99906782T ATE491723T1 AT E491723 T1 ATE491723 T1 AT E491723T1 AT 99906782 T AT99906782 T AT 99906782T AT 99906782 T AT99906782 T AT 99906782T AT E491723 T1 ATE491723 T1 AT E491723T1
- Authority
- AT
- Austria
- Prior art keywords
- treating
- diabetes
- amylin
- compounds
- type
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 title abstract 3
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 title abstract 3
- 230000000694 effects Effects 0.000 title abstract 3
- 208000002705 Glucose Intolerance Diseases 0.000 abstract 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 2
- 201000009104 prediabetes syndrome Diseases 0.000 abstract 2
- 208000011580 syndromic disease Diseases 0.000 abstract 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 2
- 229940127438 Amylin Agonists Drugs 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 239000000446 fuel Substances 0.000 abstract 1
- 230000005176 gastrointestinal motility Effects 0.000 abstract 1
- 201000001421 hyperglycemia Diseases 0.000 abstract 1
- 230000004060 metabolic process Effects 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7474698P | 1998-02-13 | 1998-02-13 | |
| PCT/US1999/002603 WO1999040928A1 (en) | 1998-02-13 | 1999-02-05 | Novel mixed amylin activity compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE491723T1 true ATE491723T1 (de) | 2011-01-15 |
Family
ID=22121450
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99906782T ATE491723T1 (de) | 1998-02-13 | 1999-02-05 | Neue verbindungen mit gemischter amylin aktivität |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1053001B1 (https=) |
| JP (1) | JP4372345B2 (https=) |
| AT (1) | ATE491723T1 (https=) |
| AU (1) | AU766653B2 (https=) |
| CA (1) | CA2320962C (https=) |
| DE (1) | DE69943039D1 (https=) |
| ES (1) | ES2356595T3 (https=) |
| WO (1) | WO1999040928A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001293557A1 (en) * | 2000-09-19 | 2002-04-02 | University Of Toronto | New inhibitors of iapp fibril formation and uses thereof |
| US8273713B2 (en) | 2000-12-14 | 2012-09-25 | Amylin Pharmaceuticals, Llc | Methods of treating obesity using PYY[3-36] |
| CA2471833A1 (en) * | 2001-11-26 | 2003-06-05 | Protemix Corporation Limited | Methods of compositions for normalizing lipid levels in mammalian tissues |
| US20070275877A1 (en) * | 2003-08-29 | 2007-11-29 | Amylin Pharmaceuticals, Inc. | Methods for Treating or Ameliorating Ghrelin-Associated Diseases and Disorders |
| RU2385878C2 (ru) | 2004-02-11 | 2010-04-10 | Амилин Фармасьютикалз, Инк. | Пептид, обладающий свойствами амилина (варианты), и его применение (варианты) |
| WO2012168431A2 (en) | 2011-06-10 | 2012-12-13 | Novo Nordisk A/S | Polypeptides |
| EP2838914B1 (en) * | 2012-04-19 | 2017-06-14 | Novo Nordisk A/S | Human amylin analogues |
| HRP20240485T1 (hr) | 2017-08-24 | 2024-07-05 | Novo Nordisk A/S | Pripravci glp-1 i njihova upotreba |
| PE20230819A1 (es) | 2020-02-18 | 2023-05-19 | Novo Nordisk As | Composiciones y usos de glp-1 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3640042A1 (de) | 1985-12-04 | 1987-06-11 | Sandoz Ag | Neue calcitoninderivate |
| NL8602950A (nl) | 1985-12-04 | 1987-07-01 | Sandoz Ag | Calcitonine-derivaten en werkwijzen voor het bereiden van deze derivaten en van farmaceutische preparaten die ze bevatten. |
| NL194729C (nl) * | 1986-10-13 | 2003-01-07 | Novartis Ag | Werkwijze voor de bereiding van peptidealcoholen via vaste fase. |
| DK163689A (da) | 1988-04-08 | 1989-10-30 | Sandoz Ag | Peptidderivater |
| US5321008A (en) | 1991-01-10 | 1994-06-14 | Amylin Pharmaceuticals, Inc. | Methods and compositions for treatment of diabetes mellitus, hypoglycemia, and other conditions |
| US5580953A (en) * | 1991-08-14 | 1996-12-03 | Amylin Pharmaceuticals, Inc. | Amylin antagonist peptides and uses therefor |
| DE69230041T2 (de) | 1991-11-19 | 2000-01-05 | Peptech (Uk) Ltd., London | Muramylverbindungen zur behandlung von septischem schock |
| WO1993014408A1 (en) | 1992-01-14 | 1993-07-22 | Amylin Pharmaceuticals, Inc. | Myotonin receptors and screening methods |
| US5376638A (en) * | 1992-09-01 | 1994-12-27 | Amylin Pharmaceuticals, Inc. | Methods for treating renin-related disorders with amylin antagonists |
| US5625032A (en) | 1993-07-21 | 1997-04-29 | Amylin Pharmaceuticals, Inc. | Selective amylin antagonist peptides and uses therefor |
| AU7685894A (en) * | 1993-09-07 | 1995-03-27 | Amylin Pharmaceuticals, Inc. | Methods for regulating gastrointestinal motility |
-
1999
- 1999-02-05 EP EP99906782A patent/EP1053001B1/en not_active Expired - Lifetime
- 1999-02-05 DE DE69943039T patent/DE69943039D1/de not_active Expired - Lifetime
- 1999-02-05 JP JP2000531179A patent/JP4372345B2/ja not_active Expired - Fee Related
- 1999-02-05 AT AT99906782T patent/ATE491723T1/de not_active IP Right Cessation
- 1999-02-05 AU AU26612/99A patent/AU766653B2/en not_active Ceased
- 1999-02-05 CA CA2320962A patent/CA2320962C/en not_active Expired - Fee Related
- 1999-02-05 WO PCT/US1999/002603 patent/WO1999040928A1/en not_active Ceased
- 1999-02-05 ES ES99906782T patent/ES2356595T3/es not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JP4372345B2 (ja) | 2009-11-25 |
| EP1053001B1 (en) | 2010-12-15 |
| CA2320962C (en) | 2011-04-19 |
| AU766653B2 (en) | 2003-10-23 |
| JP2002522355A (ja) | 2002-07-23 |
| WO1999040928A1 (en) | 1999-08-19 |
| AU2661299A (en) | 1999-08-30 |
| EP1053001A1 (en) | 2000-11-22 |
| CA2320962A1 (en) | 1999-08-19 |
| DE69943039D1 (de) | 2011-01-27 |
| EP1053001A4 (en) | 2006-01-04 |
| ES2356595T3 (es) | 2011-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69935229D1 (de) | Neue antidiabetische peptide | |
| Urva et al. | The novel dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 (GLP‐1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long‐acting GLP‐1 receptor agonists | |
| MY134820A (en) | Glucagon-like insulinotropic complexes, compositions and methods | |
| DE69943039D1 (de) | Neue verbindungen mit gemischter amylin aktivität | |
| D'Alessio et al. | Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes | |
| IL144703A0 (en) | Methods and reagents for treating glucose metabolic disorders | |
| BG104060A (en) | Diabetes treatment with thiazolyidindion and methformine | |
| NO20010982L (no) | Fremgangsmåte for å administrere insulinotropiske peptider | |
| WO2005113606A3 (en) | Fgf-21 fusion proteins | |
| KR920019347A (ko) | 당뇨병의 치료방법 | |
| ATE273996T1 (de) | Zusammensetzung zur therapie von diabetes mellitus und fettsucht | |
| Bolli et al. | Lixisenatide, a novel GLP‐1 receptor agonist: efficacy, safety and clinical implications for type 2 diabetes mellitus | |
| CY1106971T1 (el) | Συνεργητικη χρηση θειαζολιδινοδιονων με πεπτιδιο-1 που ομοιαζει με γλυκογονο και αγωνιστες αυτου για να θεραπευεται μη-ινσουλινο εξαρτωμενος διαβητης | |
| UA92451C2 (en) | Polyethelene glycol link glp-1 compounds | |
| CY1112398T1 (el) | Πυρρολιδινονες υποκατασταθεισες απο κυκλοεξυλιο ως αναστολεις της 11-β-υδροξυστεροειδικης αφυδρογονασης 1 | |
| DK0533898T3 (da) | Fremgangsmåder og sammensætninger til behandling af diabetes mellitus, hypoglykæmi og andre tilstande | |
| EA201101191A1 (ru) | Фармацевтическая композиция, включающая ингибитор sglt-2, ингибитор дпп-iv и необязательно другой антидиабетический агент, и ее применение | |
| GEP20033015B (en) | Glucagon-Like Peptide-1 Improving Beta –Cell Response to Glucose in Subjects With Impaired Glucose Tolerance | |
| EP1145717A3 (en) | Synergistic effect of a sulfonylurea and/or non-sulfonylurea K plus ATP channel blocker, and a phosphodiesterase 3 type inhibitor | |
| NO20015932L (no) | Fremgangsmåte til å behandle diabetes | |
| BRPI0412182A (pt) | composição para tratamento e/ou prevenção de disfunções associadas com diabetes melito do tipo 2 e resistência à insulina | |
| WO2005070444A8 (en) | Methods for treating acute myocardial infarction by calcitonin gene related peptide and compositions containing the same | |
| De Beaufort et al. | The incidence of Type 1 (insulin-dependent) diabetes mellitus in subjects aged 0–19 years in Luxembourg: a retrospective study from 1977 to 1986 | |
| Haldar et al. | REE and Radiogenic Sr, Nd Isotopic Variability in Saprolites formed on Metadiabase: Implications for REE Mobility and Age of Saprolitization | |
| MX2025003293A (es) | Florotaninos y alfa-fucanos para el tratamiento de la diabetes mellitus tipo 2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |